Thus with the chemotherapy-based neoadjuvant regimen yielding significantly superior pCR, and the expectation that pCR in HER2+ early breast cancer will correlate with long-term time-to-event clinical outcomes (i.e., iDFS and overall survival [OS])105–107, the current standard of care for HER2+/HR+ early breast cancer at this time (for the vast majority of patients and outside the context of participation in a clinical trial) remains a combination of chemotherapy plus dual anti-HER2 antibodies. The gene discussed is ERBB2; the disease is breast carcinoma.